Single-arm, single-center, exploratory study of Vibecotamab combined with TAS-102 in the treatment of relapsed/metastatic RAS wild-type colorectal cancer patients who have failed second-line standard therapy

Authors
Category Primary study
Registry of TrialsChinese Clinical Trial Register
Year 2026
This article has no abstract
Epistemonikos ID: daead5babfd4e996e90ceabd7bf47ef34a915db7
First added on: Oct 10, 2026